IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid...
COVID-19
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program,...
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical...
Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning...
Progressive Care Inc. Announces First Quarter 2023 Financial Results and Record Quarterly Revenues of $11.4 Million
MIAMI, FL, May 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the...
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning...
Assure Holdings Sets First Quarter 2023 Conference Call for Tuesday, May 16, 2023, at 4:30 p.m. ET
DENVER, May 12, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights
ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of MedicalSALT LAKE CITY,...
UPDATE — Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash...
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
Table 1 FDA Required Primary Efficacy Endpoint Figure 2 Study BDX-22-006 Primary Endpoint Figure 3 Study BDX-22-006Announced Positive Top-Line Final...
Palisade Bio Reports First Quarter 2023 Financial Results
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for...
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash...
Bio-Path Holdings Reports First Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients...
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with...